{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 3 of 3 results
Status:
Investigational
Source:
NCT03267303: Phase 2 Interventional Completed Narcolepsy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Enerisant is a histamine H3 receptor antagonist. In H3 receptor binding assay using (R)-α-methyl[3H]histamine, enerisant showed IC50 of 4.9 nM. Enerisant may be useful for the treatment of Alzheimer's disease, schizophrenia, etc.
Status:
Investigational
Source:
NCT03267303: Phase 2 Interventional Completed Narcolepsy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Enerisant is a histamine H3 receptor antagonist. In H3 receptor binding assay using (R)-α-methyl[3H]histamine, enerisant showed IC50 of 4.9 nM. Enerisant may be useful for the treatment of Alzheimer's disease, schizophrenia, etc.
Status:
Investigational
Source:
NCT03267303: Phase 2 Interventional Completed Narcolepsy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Enerisant is a histamine H3 receptor antagonist. In H3 receptor binding assay using (R)-α-methyl[3H]histamine, enerisant showed IC50 of 4.9 nM. Enerisant may be useful for the treatment of Alzheimer's disease, schizophrenia, etc.
